Discover the latest breakthrough in pediatric kidney health: how a groundbreaking trial is transforming the prognosis for children with autosomal dominant polycystic kidney disease using tolvaptan.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan.
Mekahli et al., Pediatr Nephrol 2023
DOI: 10.1007/s00467-023-06239-8
New Insights:
The study provides new evidence that it is feasible to assess the risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease (ADPKD), despite the lack of validated criteria for this age group. It identifies key parameters that can be used for risk estimation.
Importance:
Understanding the risk of rapid progression in pediatric ADPKD is crucial for early intervention and management. This study’s findings could help guide clinical decisions and potentially improve outcomes for young patients.
Contribution to Literature:
The research contributes to the literature by retrospectively analyzing baseline characteristics of children enrolled in a trial and establishing a consensus among pediatric nephrologists on the clinical characteristics important for assessing progression risk in pediatric ADPKD.
Results Summary:
- Out of 90 evaluable subjects, 69 (77%) had concordant primary reviews.
- By age group, the proportion considered at risk of rapid progression (mean rating ≥ 3.5) was:
- Ages 15-17: 27/34 (79%)
- Ages 12-<15: 9/32 (28%)
- Ages 4-<12: 8/24 (33%)
- Key characteristics for risk determination agreed upon include age, kidney imaging, kidney function, blood pressure, urine protein, and genetics.